INMB: INmune Bio Inc Company Profile & Statistics

About

INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States.

Info & Links

CEO

Raymond J. Tesi

Headquarters

225 NE Mizner Blvd., Suite 640
Boca Raton, FL 33432, UNITED STATES

Auditor

Marcum llp

Share holders

Employees

INmune Bio Inc Statistics

Valuation Measures

Market Capitalization²

101.54M

Enterprise Value

70.48M

Enterprise Value/EBITDA(ttm)

-1.70

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

803.95

Price to Book(mrq)

2.43

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

-26333.59%

Profit Margin(ttm)

-27194.64%

Return on Equity(ttm)

-117.48%

Return on Invested Capital(ttm)

-119.71%

Return on Assets(ttm)

-78.96%

Income Statement

Revenue(ttm)

42.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

42.00K

EBITDA(ttm)³

-41.43M

Net Income Available to Common(ttm)

-41.27M

Diluted EPS(ttm)

-2.18

Share Statistics

Beta (5Y Monthly)

1.79

52-Week Change

-52.14%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

22.17M

Dividend Yield

0.00%

Float⁴

14.37M

% Held by Insiders

35.20%

% Held by Institutions

12.72%

Balance Sheet

Total Cash(mrq)

33.55M

Total Cash Per Share(mrq)

1.51

Total Debt(mrq)

2.49M

Total Debt/Equity(mrq)

6.45%

Current Ratio(mrq)

2.59%

Quick Ratio(mrq)

2.59%

Book Value Per Share(mrq)

1.74

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.11

Free Cash Flow(ytd)

-22.35M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

INMB

INmune Bio Inc

INmune Bio Inc Profile